Memorial Sloan Kettering Cancer Center

Pembrolizumab monotherapy demonstrated superior PFS and PFS2 compared with standard-of-care chemotherapy among patients with microsatellite-instability high/mismatch repair-deficient metastatic colorectal cancer.

National Association for Proton Therapy created a physician advisory committee to provide advice on topics such as clinical research, patient education and insurance reimbursement.

An updated analysis of the phase 2 DESTINY-Breast01 study showed fam-trastuzumab deruxtecan-nxki continued to benefit women with heavily pretreated HER2-positive metastatic breast cancer.

Belumosudil conferred high overall response rates at two dose levels among patients with chronic graft-versus-host disease, according to results of the phase 2 ROCKstar study presented at the virtual ASH Annual Meeting and Exposition.

Older patients with myelodysplastic syndrome who underwent donor-matched allogeneic hematopoietic stem cell transplant had significantly improved survival outcomes compared with those who did not have a matched donor, study results showed.

Several oncology researchers received the NIH Director’s New Innovator Award.

Melissa K. Frey, MD, does not believe a woman who has just been diagnosed with ovarian cancer should be responsible for telling her relatives they also may be at risk.

Ten years ago, researchers at NCI reported use of CD19-directed chimeric antigen receptor T-cell therapy that successfully induced remission in a patient with follicular lymphoma.

The addition of stereotactic body radiation therapy to nivolumab did not improve outcomes among a cohort of patients with metastatic head and neck squamous cell carcinoma, according to a study published in Journal of Clinical Oncology.

A four-factor prognostic model identified patients with chronic lymphocytic leukemia who had poorer survival outcomes with ibrutinib, according to study results published in Journal of Clinical Oncology.